Eli Lilly reports sustained Crohn's disease treatment success

INDIANAPOLIS - Eli Lilly and Company (NYSE: NYSE:LLY), a pharmaceutical giant with a market capitalization of $783.7 billion and impressive revenue growth of 32% in the last twelve months, has announced that its drug Omvoh (mirikizumab-mrkz) has shown sustained efficacy in Crohn's disease patients over two years of continuous treatment. The VIVID-2 study results revealed that 92.9% of patients who were in clinical remission after the first year...